{"schema_version":"secwatch.filing_event.v1","accession":"0001323885-26-000032","form_type":"8-K","ticker":"ATRC","cik":"0001323885","company_name":"AtriCure, Inc.","filed_at":"2026-07-23T20:00:24+00:00","discovered_at":"2026-07-23T20:01:00.374154+00:00","generated_at":"2026-07-23T20:01:15.795199+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AtriCure Q2 2026 revenue $153.6M (+12.8% YoY); net income $9.0M vs loss a year ago","bullets":["Worldwide revenue $153.6M, up 12.8% YoY (12.4% constant currency); U.S. revenue $125.6M (+13.6%).","Net income $9.0M ($0.18 EPS) vs net loss of $0.13 per share in Q2 2025; adjusted EBITDA $27.3M (+78%).","Gross margin 77.2%, up 269 bps YoY; income from operations $9.7M vs loss of $6.2M.","Growth driven by cryoSPHERE MAX pain management probe, EnCompass clamp, AtriClip devices; international revenue $28.0M (+9.6%).","Advancing BoxX-NoAF and LeAAPS clinical trials towards data readouts."],"urls":{"canonical":"https://secwatch.observer/filing/0001323885-26-000032","json":"https://secwatch.observer/filing/0001323885-26-000032.json","markdown":"https://secwatch.observer/filing/0001323885-26-000032.md","text":"https://secwatch.observer/filing/0001323885-26-000032.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1323885/000132388526000032/0001323885-26-000032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1323885/000132388526000032/atrc-20260723.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-23T20:01:15.795199+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}